Reassuring news for patients
Women who received CAR T cell therapy for autoimmune diseases went on to have regular pregnancies and healthy babies, according to a new study. The findings were published by researchers who tracked patients over several years after their treatment.
CAR T cell therapy works by taking a patient's immune cells, reprogramming them in a lab, and putting them back to attack disease. The approach was first developed for cancer and is now being used for autoimmune conditions such as lupus and multiple sclerosis.
Until now, little was known about how the therapy affects fertility and pregnancy. Many patients of childbearing age were left with uncertainty about their options after treatment.
What the study found
The researchers followed women who became pregnant after completing CAR T cell therapy. They recorded the course of each pregnancy, the health of the mothers, and the condition of the newborns.
Most of the pregnancies progressed normally. The babies were born healthy, and the researchers found no pattern of complications linked to the therapy itself.
The study also found that the autoimmune disease remained under control during pregnancy for most participants. This matters because pregnancy can sometimes trigger flare-ups in autoimmune conditions.
What it means for care
The authors say the results support earlier and more open discussions about family planning with patients considering CAR T cell therapy. Doctors should talk about fertility preservation before treatment and about pregnancy options afterward.
The study is small, and the researchers say larger follow-ups are needed. But the early evidence is clear: CAR T cell therapy does not appear to close the door to having a family. The team plans to expand its registry to include more patients in the coming years.
Experts say the findings will help patients and doctors make better-informed decisions about a therapy that is quickly becoming a standard option for severe autoimmune disease.